These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9371896)

  • 1. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
    Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
    Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
    Solomon GD; Cady RK; Klapper JA; Earl NL; Saper JR; Ramadan NM
    Neurology; 1997 Nov; 49(5):1219-25. PubMed ID: 9371897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term study to maximise migraine relief with zolmitriptan.
    Tepper SJ; Donnan GA; Dowson AJ; Bomhof MA; Elkind A; Meloche J; Fletcher PE; Millson DS
    Curr Med Res Opin; 1999; 15(4):254-71. PubMed ID: 10640258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolmitriptan: a review of its use in migraine.
    Spencer CM; Gunasekara NS; Hills C
    Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M; Hee A; Emeribe U; Silberstein S
    CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
    Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.
    Mauskop A; Farkkila M; Hering-Hanit R; Rapoport A; Warner J
    Curr Med Res Opin; 1999; 15(4):282-9. PubMed ID: 10640260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
    Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
    CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of zolmitriptan (Zomig, 311C90).
    Lipton RB; Stewart WF
    Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.
    Geraud G; Compagnon A; Rossi A;
    Eur Neurol; 2002; 47(2):88-98. PubMed ID: 11844897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J; Sawyer J
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study.
    Visser WH; Klein KB; Cox RC; Jones D; Ferrari MD
    Neurology; 1996 Feb; 46(2):522-6. PubMed ID: 8614525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral zolmitriptan is effective in the acute treatment of cluster headache.
    Bahra A; Gawel MJ; Hardebo JE; Millson D; Breen SA; Goadsby PJ
    Neurology; 2000 May; 54(9):1832-9. PubMed ID: 10802793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
    Gallagher RM; Dennish G; Spierings EL; Chitra R
    Headache; 2000 Feb; 40(2):119-28. PubMed ID: 10759911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
    Zagami AS
    Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.
    Rothner AD; Wasiewski W; Winner P; Lewis D; Stankowski J
    Headache; 2006 Jan; 46(1):101-9. PubMed ID: 16412157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
    Geraud G; Olesen J; Pfaffenrath V; Tfelt-Hansen P; Zupping R; Diener HC; Sweet R
    Cephalalgia; 2000 Feb; 20(1):30-8. PubMed ID: 10817444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.